AI
DNTH icon

Atom Investors’s Dianthus Therapeutics DNTH Stock Holding History

Atom Investors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.63M Sell
37,228
-70,525
-65% -$6.16M 0.32% 44
2026
Q1 		$9.04M Sell
107,753
-74,107
-41% -$4.29M 0.65% 10
2025
Q4 		$7.49M Buy
181,860
+120,822
+198% +$4.68M 0.6% 31
2025
Q3 		$2.4M Buy
+61,038
New +$1.56M 0.18% 147

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Atom Investors's DNTH Position: Q2 2026 in Review

Atom Investors reduced its Dianthus Therapeutics (DNTH) stake by 65% in Q2 2026, selling an estimated $6.16M and leaving 37,228 shares worth $3.63M. The position accounts for 0.32% of the portfolio, ranked #44.

Atom Investors first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. The position peaked at $9.04M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Atom Investors held 37,228 shares of Dianthus Therapeutics worth $3.63M as of Q2 2026.
  • Atom Investors sold 70,525 Dianthus Therapeutics shares in Q2 2026, an estimated $6.16M.
  • Dianthus Therapeutics made up 0.32% of Atom Investors's portfolio in Q2 2026, its #44 holding.
  • Atom Investors first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Atom Investors's Dianthus Therapeutics position peaked at $9.04M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.